Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management

Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

CME information and select publications here.